HCI vs UPC

For growth investors, HCI Group, Inc.

(HCI) is the stronger pick with 20. 2% revenue growth year-over-year, versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). HCI Group, Inc. (HCI) offers the better valuation at 6. 2x trailing P/E (9. 3x forward), making it the more compelling value choice. Analysts rate HCI Group, Inc. (HCI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, HCI Group, Inc.

(HCI) delivered a total return of +111. 5%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: HCI returned +452. 3% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HCI Group, Inc.

(HCI) is the lower-risk stock at 0. 39β versus Universe Pharmaceuticals Inc. 's 1. 26β — meaning UPC is approximately 223% more volatile than HCI relative to the S&P 500. On balance sheet safety, HCI Group, Inc. (HCI) carries a lower debt/equity ratio of 3% versus 16% for Universe Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), HCI Group, Inc.

(HCI) is pulling ahead at 20. 2% versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). On earnings-per-share growth, the picture is similar: HCI Group, Inc. grew EPS 179. 8% year-over-year, compared to 26. 5% for Universe Pharmaceuticals Inc.. Over a 3-year CAGR, HCI leads at 22. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HCI Group, Inc.

(HCI) is the more profitable company, earning 35. 6% net margin versus -20. 6% for Universe Pharmaceuticals Inc. — meaning it keeps 35. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 31. 6% versus -16. 3% for UPC. At the gross margin level — before operating expenses — HCI leads at 41. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, HCI Group, Inc.

(HCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), +452. 3% 10Y return). Both have compounded well over 10 years (HCI: +452. 3%, UPC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HCI (Financial Services) and UPC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HCI is a small-cap high-growth stock; UPC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.